Nektar Therapeutics Reports Second Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom forecasts quarterly sales below estimates amid rising custom AI chip competition
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Nektar Therapeutics (NKTR) Tops Q2 EPS by 9c
August 4, 2022 5:18 PM EDTNektar Therapeutics (NASDAQ: NKTR) reported Q2 EPS of ($0.85), $0.09 better than the analyst estimate of ($0.94). Revenue for the quarter came in at $21.6 million versus the consensus estimate of $22.75 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
... More